<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Xu X</submitter><funding>Natural Science Foundation of Zhejiang Province</funding><funding>National Natural Science Foundation of China</funding><funding>Natural Science Foundation of Zhejiang Province (Zhejiang Provincial Natural Science Foundation)</funding><funding>National Natural Science Foundation of China (National Science Foundation of China)</funding><pagination>4237</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11102475</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>15(1)</volume><pubmed_abstract>Immune checkpoint inhibition targeting the PD-1/PD-L1 pathway has become a powerful clinical strategy for treating cancer, but its efficacy is complicated by various resistance mechanisms. One of the reasons for the resistance is the internalization and recycling of PD-L1 itself upon antibody binding. The inhibition of lysosome-mediated degradation of PD-L1 is critical for preserving the amount of PD-L1 recycling back to the cell membrane. In this study, we find that Hsc70 promotes PD-L1 degradation through the endosome-lysosome pathway and reduces PD-L1 recycling to the cell membrane. This effect is dependent on Hsc70-PD-L1 binding which inhibits the CMTM6-PD-L1 interaction. We further identify an Hsp90α/β inhibitor, AUY-922, which induces Hsc70 expression and PD-L1 lysosomal degradation.</pubmed_abstract><journal>Nature communications</journal><pubmed_title>Hsc70 promotes anti-tumor immunity by targeting PD-L1 for lysosomal degradation.</pubmed_title><pmcid>PMC11102475</pmcid><funding_grant_id>LQ24C070001</funding_grant_id><funding_grant_id>32222023</funding_grant_id><funding_grant_id>32350016</funding_grant_id><pubmed_authors>Zhou M</pubmed_authors><pubmed_authors>Xie T</pubmed_authors><pubmed_authors>Huang C</pubmed_authors><pubmed_authors>Xie Y</pubmed_authors><pubmed_authors>Wang D</pubmed_authors><pubmed_authors>Hou T</pubmed_authors><pubmed_authors>Wang F</pubmed_authors><pubmed_authors>Zhang L</pubmed_authors><pubmed_authors>Sun Y</pubmed_authors><pubmed_authors>Xia H</pubmed_authors><pubmed_authors>Chen Z</pubmed_authors><pubmed_authors>Zhao Q</pubmed_authors><pubmed_authors>Tian Y</pubmed_authors><pubmed_authors>Wu R</pubmed_authors><pubmed_authors>Cen X</pubmed_authors><pubmed_authors>Xu X</pubmed_authors><pubmed_authors>Zhou J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Hsc70 promotes anti-tumor immunity by targeting PD-L1 for lysosomal degradation.</name><description>Immune checkpoint inhibition targeting the PD-1/PD-L1 pathway has become a powerful clinical strategy for treating cancer, but its efficacy is complicated by various resistance mechanisms. One of the reasons for the resistance is the internalization and recycling of PD-L1 itself upon antibody binding. The inhibition of lysosome-mediated degradation of PD-L1 is critical for preserving the amount of PD-L1 recycling back to the cell membrane. In this study, we find that Hsc70 promotes PD-L1 degradation through the endosome-lysosome pathway and reduces PD-L1 recycling to the cell membrane. This effect is dependent on Hsc70-PD-L1 binding which inhibits the CMTM6-PD-L1 interaction. We further identify an Hsp90α/β inhibitor, AUY-922, which induces Hsc70 expression and PD-L1 lysosomal degradation.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 May</publication><modification>2026-06-02T02:20:33.283Z</modification><creation>2026-04-13T03:12:14.144Z</creation></dates><accession>S-EPMC11102475</accession><cross_references><pubmed>38762492</pubmed><doi>10.1038/s41467-024-48597-3</doi></cross_references></HashMap>